Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. Show more

15 Crosby Drive, Bedford, MA, 01730, United States

https://www.ocutx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.907B

52 Wk Range

$5.80 - $16.44

Previous Close

$8.76

Open

$8.84

Volume

3,999,650

Day Range

$8.46 - $9.04

Enterprise Value

1.249B

Cash

737.1M

Avg Qtr Burn

-54.25M

Insider Ownership

2.81%

Institutional Own.

90.13%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ReSure® Sealant Details Intraoperative management of clear corneal incision	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DEXTENZA® (dexamethasone ophthalmic insert) Details Eye disease , Allergic conjunctivitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DEXTENZA® (dexamethasone ophthalmic insert) Details Inflammation and pain following ophthalmic surgery	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AXPAXLI (OTX-TKI) (axitinib intravitreal implant) Details Non-proliferative diabetic retinopathy (NPDR)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AXPAXLI (OTX-TKI) (axitinib intravitreal implant) Details Wet age-related macular degeneration	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTX-CSI (cyclosporine intracanalicular insert) Details Dry eye disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTX-DED (dexamethasone intracanalicular insert) Details Dry eye disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PAXTRAVA™ (OTX-TIC) (travoprost implant) Details Ocular hypertension, Primary open angle glaucoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.